SCHEMBL6087307

SCHEMBL6087307

Cn1c(C(N)=O)cc2cc(OCc3cccc(NC(=O)C(CCC(=O)O)NC(C)(C)C)c3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.48
AS3MT Q9HBK9 1/20 0.43
LTA4H P09960 3/20 0.41
KDM1A O60341 2/20 0.40
RCOR1 Q9UKL0 2/20 0.40
CYSLTR1 Q9Y271 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
GALR3 O60755 1/20 0.37
GAA P10253 1/20 0.37
F10 P00742 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP10 P09238 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087646 0.88 LTA4H (0.55) SRD5A2AS3MTLTA4HKDM1ARCOR1
SCHEMBL6087655 0.88 LTA4H (0.55) SRD5A2AS3MTLTA4HKDM1ARCOR1
SCHEMBL6467439 0.82 AS3MT (0.52) SRD5A2AS3MTLTA4HKDM1ARCOR1
SCHEMBL6087100 0.82 CFD (0.55) SRD5A2LTA4HSIRT2SIRT3SIRT1
SCHEMBL6087316 0.76 SRD5A2 (0.48) SRD5A2LTA4HMEN1NPC1RAB9A
SCHEMBL6087315 0.76 SRD5A2 (0.48) SRD5A2LTA4HMEN1NPC1RAB9A
SCHEMBL6087478 0.75 SRD5A2 (0.81) SRD5A2MEN1NPC1RAB9AKMT2A
SCHEMBL6087534 0.73 SRD5A2 (0.64) SRD5A2AS3MTMEN1NPC1RAB9A
SCHEMBL6087410 0.70 SRD5A2 (0.58) SRD5A2MEN1NPC1RAB9AKMT2A
SCHEMBL6087679 0.68 CFD (0.60) SRD5A2AS3MTLTA4HSIRT2SIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7125906-B2 Indole derivatives having anti-angiogenetic activity ASTRAZENECA AB (SE) 2006-10-24 US disclosed
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization ASTRAZENECA AB (SE) 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization FLT1, FLT4, VEGFA SRD5A2 1504/4885AS3MT 4882/4885LTA4H 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.